Abstract：Objective: To study the effects of golimumab combined with leflunomide in the treatment of active rheumatoid arthritis (RA) with poor treatment effects of methotrexate (MTX). Methods: 70 patients with active RA with poor MTX treatment effects in the hospital from December 2016 to December 2018 were divided into observation group (golimumab +leflunomide, n=35) and control group (leflunomide, n=35) according to the simple random grouping. The treatment effects were observed in the two groups. Results: After treatment, the morning stiffness time in the two groups was significantly shortened, and the quantities of joint swelling and tenderness were significantly decreased (P<0.05), and the morning stiffness time and quantities of joint swelling and tenderness in observation group were significantly shorter/Less than those in control group (P<0.05). After treatment, the visual analogue pain scale (VAS) scores of patients and doctors in the two groups were significantly lower than those before treatment (P<0.05), and the VAS scores of patients and doctors in observation group after treatment were significantly lower than those in control group (P<0.05). After treatment, the levels of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and rheumatoid factor (RF) were significantly lower than those before treatment (P<0.05), and the levels of above substances in observation group were significantly lower than those in control group (P<0.05). After treatment, the levels of serum interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), plasma fibrin/fibrinogen degradation product (FDP) and D-dimer (DD) were significantly lower than those before treatment (P<0.05), and the levels of above substances in observation group after treatment were significantly lower than those in control group (P<0.05). The proportions of ARC50 and ARC70 in observation group were significantly higher than those in control group (P<0.05). There were no significant differences in the adverse drug reactions between the two groups (P>0.05). Conclusion: Golimumab combined with leflunomide has good treatment effects in active RA patients with poor MTX treatment effects. And it can effectively alleviate clinical symptoms such as morning stiffness, joint swelling and tenderness, reduce the levels of ESR, CRP, RF and serum-related inflammatory substances, and improve the treatment effects, and it does not increase the adverse reactions, thus it is worthy of clinical promotion.
潘璐, 赵华, 牛刚, 方皓. 戈利木单抗配合来氟米特治疗甲氨蝶呤疗效不佳活动性类风湿关节炎的疗效探析[J]. 河北医学, 2020, 26(2): 302-306.
PAN Lu, ZHAO Hua, et al. Exploration of Efficacy of Golimumab Combined with Leflunomide in the treatment of Active RA with Poor MTX Efficacy. HeBei Med, 2020, 26(2): 302-306.
2020, Vol. 26 
冀公网安备13080202000677号